The Novozymes stock had a good year in 2013, gaining 44%. In April, 5.3 million B shares were canceled.
The Novozymes stock is listed on Nasdaq OMX Copenhagen and included in the OMX Copenhagen 20 index (OMXC20CAP). The stock is listed under ticker code NZYM B and ISIN DK0060336014. Novozymes is registered with the Danish Business Authority under 10 00 71 27.
|Novozymes’ stock (DKK)||2013||2012|
|Share price, year-end||228.9||159.2|
|Total market value, year-end (billion)*||73.2||51.7|
|Earnings per share, diluted||6.93||6.33|
|Dividend per share||2.50**||2.20|
|* All A and B shares multiplied by the price of the B share.|
###GRAF: Indexed share performance###
Novozymes' share price increased by 44% during the year. In comparison, the OMXC20CAP gained 32%, the MSCI Pan Europe Index gained 16%, and the Dow Jones Sustainability World Index was up 20%.
The average daily trading volume of Novozymes' stock in 2013 was 424,988 shares, or DKK 84 million, making it the seventh most actively traded company on Nasdaq OMX Copenhagen, the same rank as in 2012. At year-end, the total market value of Novozymes' B shares was DKK 60.9 billion, and the value of the nontraded A shares was DKK 12.3 billion, assuming the same value per share as for the B shares.
Over the past five years, Novozymes' stock has generated a compound average annual return to shareholders of 22% (23% including dividends). This can be compared with a five-year compound average return without dividends of 20% for the OMXC20, 9% for the MSCI Pan Europe Index and 11% for the Dow Jones Sustainability World Index.
As resolved at the Annual Shareholders’ Meeting in February 2013, 5.3 million B shares were canceled in a capital reduction on April 5, 2013.
“In 2013, Novozymes was named as Biotechnology Industry Leader for the 12th time and awarded a Gold Class rating for 2012 performance in RobecoSAM's Sustainability Yearbook 2013.”###GRAF: FIVE-YEAR Indexed share performance###
The Board of Directors proposes that the Annual Shareholders' Meeting 2014 approve a dividend of DKK 2.50 per share for the 2013 financial year. This will result in an expected total dividend payment of approximately DKK 786 million, corresponding to a payout ratio of 35.7%.
As announced on December 10, 2013, in relation to the formation of The BioAg Alliance with Monsanto, Novozymes expects to initiate a new stock buyback program in 2014 worth up to DKK 2 billion.
|Dividends (DKK million)||786*||687||599||504||358|
|Stock buybacks (DKK million)||0||832||400||0||0|
|Total (DKK million)||786*||1,519||999||504||358|
|Net profit (DKK million)||2,201||2,016||1,828||1,614||1,194|
|Payout ratio (%)||35.7*||34.0||32.8||31.2||30.0|
|Number of shares outstanding,
|Dividend per share (DKK)||2.50*||2.20||1.90||1.60||1.15|
Dividend dates 2014
|Resolution adopted at the Annual Shareholders' Meeting||February 26|
|Last day of trading with right to dividend for 2013||February 26|
|First day of trading without right to dividend for 2013||February 27|
|Disbursement of dividend||March 4|
The following companies have analysts covering Novozymes’ stock:
|ABG Sundal Collier||Jefferies & Company|
|Alm. Brand Markets||J.P. Morgan|
|CA Cheuvreux Nordic||Kempen & Co.|
|Credit Suisse||Nykredit Markets|
|Danske Markets||SEB Enskilda Equities|
|DnB NOR Markets||Standard & Poor's|
|Handelsbanken Capital Markets||UBS|
Providing information on sustainability performance to analysts, rating agencies and asset managers is an important element of Novozymes' interaction with shareholders. We continuously seek to improve our sustainability reporting and processes, and value this interaction highly. In 2013, Novozymes was:
Novozymes' common stock
|A stock||B stock||Total|
|Common stock (DKK)*||107,487,200||531,912,800||639,400,000|
|Number of shares||53,743,600||265,956,400||319,700,000|
|Number of votes||1,074,872,000||531,912,800||1,606,784,800|
|Voting rights (%)||66.9||33.1||100|
|* Common stock equals 319,700,000 shares with a nominal value of DKK 2 per share|
Novozymes' common stock consists of two types: A shares and B shares, both with a nominal value of DKK 2 per share. All A stock is held by Novo A/S, and an A share carries 10 times as many votes as a B share.###GRAPH: Shareholder distribution of B common stock###
At the end of 2013, Novo A/S held 25.9% of the total common stock and, through its holding of the A stock and a proportion of the B stock (29,131,400 shares), controlled 70.5% of the votes. Novo A/S is wholly owned by the Novo Nordisk Foundation, and Novozymes is therefore included in the consolidated financial statements of the Novo Nordisk Foundation. Novo A/S is domiciled in Hellerup, Denmark.
At year-end, Novozymes had roughly 49,000 shareholders, of whom 99% were private shareholders in Denmark. Twenty institutional investors, including Novo A/S, owned approximately 60% of the B shares. Around 65% of the B shares were held outside Denmark.
Novozymes held 2.1% of the B stock, equivalent to 1.7% of the total common stock.
Besides Novo A/S, only one shareholder, Baillie Gifford & Co., held more than 5% of Novozymes' common stock on December 31, 2013.
“The average daily trading volume of Novozymes' stock in 2013 was 424,988 shares, or DKK 84 million, making it the seventh most actively traded company on Nasdaq OMX Copenhagen.”
|Group financial statement for 2013||Jan. 21, 2014|
|Annual Shareholders' Meeting 2014||Feb. 26, 2014|
|Interim report for the first 3 months of 2014||April 24, 2014|
|Interim report for the first half of 2014||Aug. 14, 2014|
|Interim report for the first 9 months of 2014||Oct. 23, 2014|
|Group financial statement for 2014||Jan. 20, 2015|
Visit our Investor site at www.novozymes.com for investor relations guidelines, presentations, tools and downloads, Group financial statements and other information for both private and institutional shareholders.
If you have questions for Investor Relations, please contact:
Thomas Steenbech Bomhoff
Head of Investor Relations
Tel.: +45 4446 1226
Senior Investor Relations Manager, U.S.
Tel.: +1 919 494 3483
Senior Investor Relations Manager, Europe
Tel.: +45 4446 0134